A new study has brought fresh hope for patients living with a serious heart condition known as transthyretin amyloid cardiomyopathy, or ATTR-CM.
This disease is not widely known, but it can have severe and life-threatening effects. Researchers have now found that a simple blood marker may help doctors better understand how the disease will progress and which patients are at the highest risk.
ATTR-CM is a condition where a protein called amyloid builds up inside the heart. Over time, these deposits make the heart walls thicker and stiffer. Because the heart becomes less flexible, it cannot pump blood as effectively as it should. This is why the condition is often described as a “stiff heart.”
As the disease worsens, patients may experience symptoms such as swelling in the legs or abdomen due to fluid buildup, extreme tiredness, and irregular heartbeats. Eventually, many patients develop heart failure. Without treatment, the average survival time is only around three years, which makes early and accurate diagnosis very important.
The study was led by Dr. Pablo García-Pavía, a cardiologist and researcher in Spain. It was published in the journal Circulation. The research focused on a substance in the blood called mid-regional pro-adrenomedullin, or MR-proADM. This is a biomarker, which means it is a measurable sign in the body that can give information about disease.
MR-proADM is already known to be linked with disease severity in several conditions, including serious infections like sepsis. The researchers wanted to find out if it could also help predict how ATTR-CM would develop in patients.
To explore this, the team studied patients diagnosed with ATTR-CM in hospitals in Spain. They then tested their findings in two additional groups of patients from other countries, including one group from the United States and another from a large clinical trial. This helped confirm that the results were consistent and reliable.
The findings showed that patients with higher levels of MR-proADM were more likely to have worse outcomes. These patients had a higher risk of heart failure events and were more likely to die from the disease. Importantly, this biomarker provided information that traditional clinical tests could not fully capture.
This is significant because predicting how ATTR-CM will progress has been a major challenge for doctors. While new treatments have been developed in recent years, it is still difficult to know which patients will benefit the most or need closer monitoring.
By using MR-proADM levels, doctors may be able to identify high-risk patients earlier. This could allow for more personalized care, such as more frequent check-ups, earlier treatment, or adjustments in therapy.
Looking at the study in more detail, it has several strengths. It included multiple patient groups and confirmed the findings across different populations, which increases confidence in the results.
However, like all research, it also has limitations. The study mainly shows a strong association between MR-proADM levels and disease outcomes, but it does not prove that the biomarker directly causes these outcomes.
More research will be needed to understand how this marker can be used in everyday clinical practice and whether it can improve long-term patient survival.
Overall, the study represents an important step forward. It highlights the growing role of biomarkers in modern medicine and shows how they can help guide more personalized treatment decisions. For patients with ATTR-CM, this could mean better care and a clearer understanding of their condition.
If you care about heart health, please read studies about top 10 foods for a healthy heart, and how to eat right for heart rhythm disorders.
For more health information, please see recent studies about how to eat your way to cleaner arteries, and salt and heart health: does less really mean more?
Source: CNIC.
